Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;15(7):377-386.

Management of Barrett Esophagus Following Radiofrequency Ablation

Affiliations

Management of Barrett Esophagus Following Radiofrequency Ablation

Craig C Reed et al. Gastroenterol Hepatol (N Y). 2019 Jul.

Abstract

Radiofrequency ablation (RFA) effectively treats dysplastic Barrett esophagus (BE), reduces the risk of esophageal adenocarcinoma (EAC), and infrequently produces complications. Complications of RFA include chest discomfort, esophageal stricturing, and bleeding. However, chest discomfort is usually transient and mild, strictures are generally amenable to dilation, and clinically significant bleeding is rare. Following RFA, intestinal metaplasia recurs at a rate of approximately 10% per patient year of follow-up time. Postablation dysplastic BE and EAC are rare. Moreover, recurrent disease is generally responsive to further endoscopic therapy and is associated with a benign clinical course. Although RFA is effective at producing low rates of postablation EAC and dysplastic recurrence, data suggest that current consensus guidelines for postablation surveillance are overly aggressive, as they mirror those for treatment-naive cohorts. Future guidelines may attenuate surveillance intervals, reducing the burden of endoscopic surveillance while providing for adequate detection of recurrent disease. Additional studies are needed to determine the length of time patients should ultimately remain in surveillance programs. Uncertainty exists regarding the appropriate application of chemopreventive measures (including proton pump inhibitors, aspirin, and statins) and novel imaging and sampling modalities (such as optical coherence tomography and wide-area transepithelial sampling) to reduce the risk of recurrent disease and sampling error, respectively. These uncertainties represent targets for future investigations.

Keywords: Barrett esophagus; complications; durability; dysplasia; radiofrequency ablation.

PubMed Disclaimer

Conflict of interest statement

Dr Shaheen receives research funding from Medtronic, CSA Medical, Interpace Diagnostics, and CDx Medical. Grant money from NIH Award K24DK100548 supported this research. Dr Reed has no relevant conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Kaplan-Meier plot of intestinal metaplasia recurrence among patients who achieved complete eradication of intestinal metaplasia (CEIM) after radiofrequency ablation (n=1634). Modified with permission from Pasricha S et al.
Figure 2.
Figure 2.
Kaplan-Meier plot of intestinal metaplasia recurrence among patients who achieved complete eradication of intestinal metaplasia (CEIM) after radiofrequency ablation, with pretreatment histology of nondysplastic Barrett esophagus (BE), indefinite for dysplasia, low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal carcinoma (IMC). Modified with permission from Pasricha S et al.

Similar articles

Cited by

References

    1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB.American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of Barrett’s esophagus Am J Gastroenterol. 2016111130–50.quiz 51 - PMC - PubMed
    1. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–1831. - PubMed
    1. Zagari RM, Fuccio L, Wallander M-A et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–1359. - PubMed
    1. Johansson J, Håkansson H-O, Mellblom L et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. ScandJ Gastroenterol. 2005;40(8):893–902. - PubMed
    1. Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–976. - PubMed

LinkOut - more resources